October 19, 2011 |
Johnson & Johnson, blaming some of its problems on the closed McNeil Consumer Healthcare facility in Fort Washington, reported a 6.3 percent drop in profits for the third quarter compared with the same period in 2010. Company officials said in a news release and a conference call with Wall Street analysts that domestic sales and revenue were again hurt in part by the extra costs and lack of income from over-the-counter medicines that had been produced at the plant in Fort Washington.
January 25, 2012 |
The McNeil Consumer Healthcare plant in Fort Washington, Montgomery County, will not resume production until at least 2013, Johnson & Johnson's chief executive officer, Bill Weldon, said Tuesday as the company reported 2011 full-year and fourth-quarter financial results. Recalls, repairs, litigation, and costs related to the acquisition of Synthes Inc. played a big part in J&J's profit dropping 88.8 percent in the fourth quarter of 2011 compared with the same period a year earlier.
October 19, 2005 |
Johnson & Johnson said yesterday that it was considering alternatives to its $25.4 billion offer for heart-device-maker Guidant Corp., which is facing product recalls and a possible federal inquiry. The acknowledgment, long awaited by Wall Street analysts, whacked Indianapolis-based Guidant's stock by 11 percent while leaving shares of Johnson & Johnson, based in New Brunswick, N.J., almost unchanged. The Guidant acquisition would be among the biggest for Johnson & Johnson, whose expansive merger strategy has made it a player in most health-care markets.
October 18, 1993 |
Breaking into the children's market for dental products could be a tough sell for pharmaceutical companies, but Johnson & Johnson found a way to reach into those little mouths with an ad campaign created by local commercial designers. "Make it fun" was the directive Johnson & Johnson gave to Minkus & Associates of Villanova for a brochure touting its ACT for Kids dental floss and mouth rinse. "They wanted us to tell a story that would appeal to the kids and to make it fun and entertaining," said Robert Minkus, president of the graphic arts firm that designs corporate logos and consumer packaging.
January 20, 2003 |
When Johnson & Johnson paid $4.9 billion for Centocor Inc. in 1999, some Wall Street analysts were skeptical, saying the big drug company had overpaid for the Malvern biotechnology firm. But three years later, nobody doubts that the investment was a good deal for the pharmaceutical and health-care-products giant, with 198 operating companies in 54 countries, and for Centocor, which is flourishing. Sales of the crown jewel of Centocor - the rheumatoid-arthritis and Crohn's-disease medicine Remicade - have jumped 500 percent, from $200 million in 1999 to the $1.2 billion that is expected to be reported when Johnson & Johnson announces 2002 financial results tomorrow.
March 28, 2001 |
Shares of Johnson & Johnson, the fourth-biggest U.S. drugmaker, fell 2.5 percent yesterday on concern that the company's $12.3 billion stock purchase of Alza Corp. could hurt profit growth. Johnson & Johnson shares fell $2.13 to $83.25, having touched $80.50 earlier in the day. Alza's shares rose 25 cents to $39. Analysts said Johnson & Johnson's purchase of Alza, announced yesterday, was aimed at making it easier for the company to offer new ways for patients to take its drugs.
April 20, 2007 |
Johnson & Johnson said yesterday that it has begun construction of a $181 million building at its Spring House complex that will add 120 jobs and become the East Coast "hub" for its early-stage drug-discovery research and development. The 150,000-square-foot building will add laboratories, clinical development and office space. It is scheduled to be completed in 2009. Johnson & Johnson Pharmaceutical Research & Development L.L.C. now employs 680 in Spring House, where the company said prescription medicines, including Topamax, Ultram and Ultracet, were developed.
December 17, 2005 |
Shares of a Chester County maker of insulin pumps jumped more than 30 percent yesterday after Johnson & Johnson said it had agreed to acquire the company for about $518 million. The purchase of Animas Corp. will give Johnson & Johnson immediate entry into the fast-growing market for insulin-delivery pumps, the New Brunswick, N.J., maker of health products said. Animas' pumps allow diabetics to receive continuous infusions of insulin. After the deal closes, Animas, which was founded in 1996 and has 350 employees, is expected to operate as a stand-alone entity under LifeScan Inc., a Johnson & Johnson subsidiary that sells systems to monitor blood glucose.
May 24, 2001 |
Johnson & Johnson Vision Care Inc. has agreed to pay up to $60 million to settle an antitrust case alleging that the company was able to charge artificially high prices because it blocked pharmacies and mail-order companies from its distribution network. The suit was filed by 32 state attorneys general, including Pennsylvania's. It alleged that the Johnson & Johnson unit and two other contact-lens manufacturers conspired with the American Optometric Association to keep their products out of distribution channels that did not have an optometrist on site.
April 18, 2001 |
Johnson & Johnson, maker of Acuvue contact lenses, has agreed to pay up to $860 million to settle complaints that the New Brunswick health-care company instructed consumers to throw away one-day lenses that could have been worn for up to 14 days. Company documents included in the suit indicate that Acuvue and 1-Day Acuvue lenses are the same product. An estimated six million contact lens wearers unnecessarily spent $1.1 billion since 1994 because of misleading advertising and packaging, according to a suit filed by consumers in 1996 in New Jersey Superior Court in Camden.